|
France-AT-AT Azienda Directories
|
Azienda News:
- Major Breakthrough: SPMs, Resolving Inflammation in the 21st . . .
Research suggests that SPMs can be particularly valuable for asthma, arthritis, diabetes, atherosclerosis, and cognitive decline SPMs have also been used very effectively to treat gut problems, particularly leaky gut syndrome and irritable bowel disease, and to aid recovery in bone and muscle injuries
- Spontaneous primary pneumomediastinum: is it always benign?
Background Spontaneous Pneumomediastinum is a rare disease It could be a simple and self-limited condition or be a life-threatening complication of underlying diseases The therapeutic options also differ by the cause This systematic review was done to provide, as far as we know, the first attempt to broadly assess the clinical feature, predisposing factors, possible management, and outcome
- Spontaneous Pneumomediastinum: A Rare Disease Associated with . . .
Spontaneous pneumomediastinum (SPM) is rare in pediatric practice, with an incidence of about 1 30000 emergency department referrals 1, 2 and an average age of 17 5 to 25 years 1, 2, 3 SPM is self-limiting and benign in nature, and it usually occurs in young healthy men without any trigger events or diseases 1, 2, 4 A pressure gradient exists
- UpToDate
Some authors distinguish between primary SPM (in which there is no underlying lung disease that would predispose the individual to air leak) and secondary SPM (in which there is an underlying airway disease, such as cystic fibrosis or asthma)
- Spontaneous Pneumomediastinum: Time for Consensus - PMC
Patients with certain pre-existing pulmonary diseases showed a greater propensity for the presence of free air in the mediastinal cavity SPM must be diagnosed and managed promptly due to rare, but serious complications and any chest pain with an unknown etiology should contain SPM in the differential diagnosis
- Specialized pro-resolving mediators in cardiovascular diseases
While the specific mechanisms underlying impaired SPM production and efferocytosis in these diseases are incompletely understood, the subcellular localization of 5-lipoxygenase (5-LOX) was recently shown to be a critical determinant of whether this enzyme produces pro-inflammatory leukotrienes or SPM in macrophages
- Spontaneous pneumomediastinum: experience in 18 patients . . .
Of those, 18 were diagnosed with SPM Therefore, the incidence of SPM in our study was approximately 1:102,000 Of the 18 patients diagnosed with SPM, 66 7% were male (the youngest being 18 years old and the oldest being 87 years old), and the mean age was 35 4 ± 24 7 years The mean length of hospital stay was 10 5 ± 9 9 days
- The dual role of lipids in chronic kidney disease: Pathogenic . . .
The SPM MaR1 has also emerged as a promising therapeutic agent for kidney disease MaR1 treatment attenuated renal inflammation and fibrosis in a mouse model of LPS-induced acute kidney injury, with evidence of reduced renal tubule damage and inflammatory pathway activation [ 133 ]
|
|